Upload
pranav-ghabroo
View
217
Download
0
Embed Size (px)
Citation preview
7/28/2019 Wood_Dave
1/17
Compulsory Licensing On
Patents in the US, China,
Japan, Germany, and India
Presented by:
Jon Wood, Bridgestone Americas
Raj S. Dav, Morrison Foerster
7/28/2019 Wood_Dave
2/17
Introduction
Compulsory License
The government, rather than the patent
owner, grants a company a non-exclusive
license to make, use or sell the patented
technology
The government, not the patent owner, setsthe terms of the license, including the royalty
7/28/2019 Wood_Dave
3/17
Criteria for Compulsory LicensingPublic welfare
Non working of invention
Exploitation of an improvement invention
Publicwelfare
Nonworking
Improvementexploitation
US No No
No
China Yes Yes YesJapan Yes Yes Yes
Germany Yes No No
India Yes Yes No
7/28/2019 Wood_Dave
4/17
Compulsory Licenses
Why They Exist
To correct market failures
Generally considered good for society
Tempers the exercise of market powerDiscourages abuse of a patent
How They Are Obtained
Private party files an application to the government
Government reviews the application, and if
appropriate, grants the license
7/28/2019 Wood_Dave
5/17
Laws For Compulsory Licenses
InternationalTRIPS Article 31Non-Voluntary license to domesticproducers without authorization of the right holder
under national emergency or extreme urgency so
long as due process requirements are met
Paragraph 6 of the Doha Declaration
National (in many nations except the U.S.)Failure to work the patent
Public Interest Reasons (e.g., pharmaceuticals for a
public health emergency)
7/28/2019 Wood_Dave
6/17
The United States
General Rule No compulsory licensing regime,per se
Exceptions 28 U.S.C. 1498
Allows the U.S. to use an invention covered by a U.S. patentwithout license
Patent owners remedy is an action against the U.S. for recovery
of reasonable compensation
Federal Trade Commission Guidelines for Licensing of
Intellectual Property
Anti-trust
Merger/Acquisition
Certain U.S. laws (e.g., Clean Air Act)
7/28/2019 Wood_Dave
7/17
The United States, cont.
Overall
Compulsory licenses have rarely been
granted
7/28/2019 Wood_Dave
8/17
China
Compulsory licenses are only applicable toinvention patents and utility patents not designpatents
No compulsory license has been granted in China
Three situations where a compulsory licensecould be granted In case of unreasonable refusal to license
Public InterestNational emergency or an extraordinary state of affairs occurs
Exploitation of an improvement invention requiringlicense on the dominant patent
7/28/2019 Wood_Dave
9/17
China, cont.
If granted, a compulsory license must
Be non-exclusive
Pay a reasonable fee to the patentee, decided by both
parties through consultation
Be predominately for the supply of the domestic market only
Shall stipulate the scope and time for exploitation
Permitted judicial review of
Decision to grant or reject a compulsory license
Adjudication of the licensing fee
Decision to terminate a compulsory license
7/28/2019 Wood_Dave
10/17
Japan
Three instances where a compulsory license could
be granted Non-working patentee
Exploitation of an improvement invention requiringlicense on the dominant patent
Public interest
No compulsory license has been granted in Japan U.S. and Japan have an agreement not to issue a
compulsory license with regard to improved inventions,except for correction of unfair competition or approval ofpublic or non-commercial utilization
7/28/2019 Wood_Dave
11/17
Germany
Compulsory licensing in general
Public welfare
A national government can issue an order allowing
everybody to use the invention
User pays fee to the government, which then pays
a justified compensation to the patentee (not
necessarily all of the fees collected)
Requirements are very severe to grant compulsorylicense for the public welfare
7/28/2019 Wood_Dave
12/17
Germany, cont.
Conditions for compulsory licensing
A voluntary license must be denied
The patent must be granted
Public interest must be present Presumed if the use of the invention by a licensee has a
higher value compared with the interest of the patentee
7/28/2019 Wood_Dave
13/17
India
India has never granted a compulsory
license
India has not finalized the rules for the
Third Patent Amendments (2005), so
interpretation of the rules is a work in
progress
7/28/2019 Wood_Dave
14/17
India (cont.)The 2005 Amendments specify
A compulsory license may be granted after 3years of issuance of a patent if
The patent is not worked in India Is importation working?
Reasonable requirements of the public are notsatisfied
The patented invention is not available to the public at areasonable price
The patented products prejudice or harm existingdomestic trade or industry
The patented products fail to develop the market forexports
7/28/2019 Wood_Dave
15/17
India, cont.
Changes in compulsory licensing by the Patents
(Amendment) Act, 2005
Substantive
Applications claiming pharmaceutical inventions submittedbetween 1999 and 2005 will be subject to an automatic
compulsory license to generic companies if the generic
companies were producing the said drug prior to 2005 and
continue to produce the drug after the issuance of the patent
ProceduralCan only apply for a compulsory license if a voluntary license
cannot be obtained within 6 months from the start of
negotiations
7/28/2019 Wood_Dave
16/17
Summary
Despite detailed legislative guidelines, countries have littleexperience with compulsory licensing outside of the anti-trust area Perhaps the availability of compulsory licensing is sufficient to encourage
patentees to grant voluntary licenses
A country that grants compulsory licenses is likely to find its efforts topartner with companies in the future adversely affected, as it wouldcreate a less stable investment climate
Furthermore, it is questionable whether a compulsory license wouldreally be useful in the case of high-technological products Years of additional research results in trade secrets and undisclosed
information that the patent does not cover, which may be necessary toproduce a productive patented invention
7/28/2019 Wood_Dave
17/17
AcknowledgementsThe presenters acknowledge the valuable
contributions of the following co-authors: Ms. Susan Finston, formerly Vice President of
Pharmaceutical Association of America, President, FinstonConsulting, LLC
Ms. Zhongyi Tao, graduate student, Peking University LawSchool
Mr. Zheng Zha, attorney, Freshfields Bruckhaus Deringer,Beijing, China
Yukio Mr. Nagasawa, former Judge of Tokyo High Court,
and now with Abe, Ikubo & Katayama, Tokyo, Japan, alongwith Mr. Hirokazu Honda and Mr. Makoto Hattori
Mr. Heinz Goddar, partner, Boehmert & Boehmert, Munich,Germany.
Mr. Shaun Fox, law student, University of Akron